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Randomised trials are generally performed from a frequentist perspective, which can conflate 
absence of evidence with evidence of absence. The RECOVERY trial evaluated convalescent plasma 
for patients hospitalised with COVID-19, concluding there was no evidence of an effect. Re-analysis 
from a Bayesian perspective is warranted. 
Methods: 
Outcome data was extracted from the RECOVERY trial by serostatus and time of 
presentation. A Bayesian re-analysis with a wide variety of priors 
(vague, optimistic, sceptical and pessimistic) was performed calculating the posterior probability for: 
any benefit, an absolute risk difference of 0.5% (small benefit, number needed to treat 200), and an 




Across all patients, when analysed with a vague prior the likelihood of any benefit or modest benefit 
with convalescent plasma was estimated to be 64% and 18% respectively The 
estimated chance of any benefit was 95% if presenting within 7 days of symptoms, or 17% if 
presenting after this.  In patients without a detectable antibody response at presentation, the 





Bayesian re-analysis suggests that convalescent plasma reduces mortality by at least 1 percentage 
point among the 39% of patients who present within 7 days 
of symptoms, and a 67% chance of the same mortality reduction in the 38% who are seronegative at 
the time of presentation. This is in contrast to the results in people who already have antibodies 
when they present. This biologically plausible finding bears witness to the advantage of Bayesian 
analyses over misuse of hypothesis tests to inform decisions. 
   
 
   
 
Introduction: 
Convalescent plasma (CP) – blood components from patients recovered from an infection - has been 
used for more than a century to treat infections, with widespread use in the 1920’s and 30’s for 
pneumococcal infections and scarlet fever, before falling out of favour with the development of 
antibiotics.1 The principle is that of ‘passive immunisation’ – passing antibodies from those 
recovered from infection to those naïve to it, thereby providing a degree of protection from that 
specific agent.2 It is therefore unsurprising that interest in the use of CP to prevent and treat COVID-
19 has been widespread.1 Unfortunately, despite best efforts, most of this usage has occurred 
outside of randomised controlled trials (RCT) with >100,000 doses given in the US alone. 3   
Fortunately, the RECOVERY collaborative group have recently reported the largest randomised 
control trial of CP in hospitalised patients with COVID-19.4 The authors conclude that CP provided no 
benefit, with observed mortality equal in both arms:  1399 (24%) of 5795 patients allocated to 
convalescent plasma and 1408 (24%) of 5763 patients allocated to usual care died within 28 days 
(rate ratio [RR] 1·00; 95% confidence interval [CI] 0·93 to 1·07; p=0·95). They also conclude there 
was no difference across pre-specified subgroups including those with detectable SARS-CoV-2 
antibody tests at the time of randomisation (seropositive group), 19% versus 18% (RR 1·06; 95% CI, 
0·94 to 1·19) and seronegative patients, 32% versus 34% (RR 0·96; 95% CI, 0·85 to 1·07); with 
test for interaction p=0.23. In particular, they note, on the advice of the Drug Safety and 
Monitoring Committee (DMC), that: “there was no convincing evidence that further recruitment 
would provide conclusive proof of worthwhile mortality benefit either overall or in any pre-specified 
subgroup.” In the United Kingdom, this data has been taken by the regulator as strong evidence of a 
null effect, leading the Medicines Health Regulatory Authority (MHRA), the UK medicines regulator, 
to recommend against the use of CP in patients hospitalised with COVID-19, effectively removing the 
therapy in the National Health Service (NHS), with many editorials agreeing with the authors this 
proves no effect.5,6 
Before accepting that CP is ineffective in hospitalized patients, it is important to recognise the clear 
distinction between patients who are likely to benefit and those who are not. 
The therapeutic 
mechanism of convalescent plasma and monoclonal antibody (e.g. REGN-COV2) treatments is by 
passive immunisation – the gifting of antibodies. These antibodies (collected from donated patients), 
develop in most people by 7-10 days, as part of the normal immune response. It is not surprising to 
think that the greatest (or any) benefit of CP would only occur in patients who present early or are 
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already have antibodies or have developed their own immune response. Previous literature from 
SARS supports this distinction7,8, as well as data clearly identifying a protective effect of monoclonal 
antibodies (manufactured antibodies, rather than donated) in early COVID-19 trials, with much 
weaker effects in hospitalised patients later in the disease course.9–12 Immunological data and cases 
of persistent infection show that failure of an early antibody response is associated with both severe 
disease and, in patients without any antibodies, the risk of persistent disease.13,14Others have also 
argued that seropositivity is a reason for failure of convalescent plasma.15 
On that background, it is logical to analyse the data from patients who are seronegative (hypothesed 
more likely to benefit) separately from those who are seropositive (hypothesed less likely to 
benefit). Likewise, it is rational to analyse the data by time from symptom onset, given that the 
only positive trial of convalescent plasma occurred with treatment given within 72 hours.16  
 Although subgroup analyses can be complicated by chance imbalances, lower power, and issues of 
multiple testing, they are appropriate to generate hypotheses and could be used in support of the 
argument of not disregarding CP as a potential treatment too soon.17,18 Moreover, conflating 
absence of evidence for a small effect with evidence of no effect further risks discarding a therapy 
which could still have a meaningful benefit.  We therefore sought to undertake a Bayesian re-
analysis to estimate the probability of (a) any benefit (b) a small benefit (which we 
define as equivalent to a number needed to treat of at most 200), and (c) a modest benefit 
(equivalent of a number needed to treat of at most 100)
 
for the all patients and for both subgroups specified above. 
 
Methods: 
We extracted the intention to treat results from the RECOVERY trial both overall and for pre-
specified subgroups: seronegative, seropositive, less than or equal to seven days since symptom 
onset and more than 7 days since symptom onset. These two subgroups 
(antibody status and time from onset) were selected on the basis of the  
scientific justification described above
. There was no granular data available to combine these two subcategories. 
We used the ‘bayes’ function STATA version 16 (Statacorp, College Station, TX) to calculate 
 posterior probabilities. We calculated the probabilities of 








   
 
   
 
as absolute risk difference of at least 0.5% (number needed to treat <=200) and (c) a modest benefit 
which we define as a risk difference of at least 1% (number needed to treat <=100). These risk 
differences were chosen after internal discussion between the study authors regarding what would 
be considered an important effect size considering the complexity and challenges in using 
convalescent plasma. By nature, they are subjective, but reflect effect sizes that might be salient 
to patients, their families and clinicians. 
As suggested by a recent review on Bayesian re-analysis in COVID-19,19 we chose four probability 
assumptions to account for varying prior views: 1. Vague (no information (mean risk difference (RD) 
0, SD 10,000)) 2.Optimistic (10% risk of harm: mean RD 0.01, SD 0.007) 3. Sceptical (tightly around 
the null: mean RD 0, SD 0.007) 4. Pessimistic (10% chance of benefit (mean RD –0.005, SD 0.0036). 
Posterior probabilities were computed from binomial regression models. Posterior density function 
graphs were produced for each prior assumption. 
All code used to generate these figures is available in the appendix.  
All code used to generate these figures is available in the appendix.  
All code used to generate these figures is available in the appendix.  
Results: 
Table 1 presents the posterior probabilities of benefit for each prior. 
 
 
Across the whole trial population, the estimated chance of any benefit is around 65%, with little 
difference across all prior assumptions. The posterior probability of a 
modest benefit (preferring treatment arm) is around 19 % across all prior assumptions.  T
he associated posterior density functions are available in the supplementary appendix, as 
he associated posterior density functions 
are available in the supplementary appendix, as supplementary figures. 
In the seronegative subgroup, the estimated likelihood of any benefit is greater, at around 90%, 
across all prior assumptions. The estimated chance of a risk difference (modest benefit) of >1% is 
also high (more than 66% across all three priors), and varied little between prior assumptions. This 
contrasts with the seropositive arm,  where the estimated chance of any benefit is only 20%, 
and with a very small (3%) chance of a modest benefit (NNT<=100). 
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These results are mirrored in the early treatment sub-group, with an around 95% 
chance of benefit in patients who were treated within 7 days of symptom onset. The chance of a 
modest benefit (NNT<=100) was about 80% across all prior assumptions. 
However, in patients who present after 7 days, the chance of convalescent plasma providing any 




   
 
   
 
Table 1: Estimated posterior probabilities of benefit for a variety of prior assumptions 
 Vague prior Optimistic prior: Sckeptical prior Pessimistic prior 
Whole trial (n = 11,558) 
Any benefit: 64% 65% 64% 62% 
Small benefit  43% 41% 40% 38% 
Modest rate 
benefit  
20% 19% 19% 18% 
Seronegative subgroup (n = 3,67611) I tihnk this should be 3676=2016+1660 
Any benefit 90%86% 91%87% 8691% 8691% 
Small benefit 79%84% 78%85% 7785% 7884% 
Moderate 
Modest benefit 
68%74% 68%76% 6676% 6773% 
Seropositve subgroup (n = 5,888) 
Any benefit 20% 23% 21% 21% 
Small benefit 9% 11% 11% 10% 
Modest benefit 3% 4% 4% 4% 
=<7 days since symptom onset (n = 4466) 
Any benefit 95% 95% 95% 95% 
Small benefit 90% 90% 90% 90% 
Modest benefit 80% 82% 82% 80% 
> 7 days since symptom onset (n = 7086) 
Any benefit 17% 17% 17% 17% 
Small benefit 7% 8% 7% 7% 
Modest benefit 3% 3% 2% 2% 
Vague prior: N(0, SD=10,000); Optimistic prior: N(0.01, SD=0.007); Skeptical prior: N(0,SD=0.007); 
Pessimistic prior N(-0.01, SD=0.0036). Small benefit defined as a risk difference >0.5% (equivilanet to 












   
 





The RECOVERY trial has been a paradigm in a rapid, pragmatic, approach to trialling new therapies in 
a pandemic. Good practice requires a firm, pre-specified analysis plan with clear, pre-defined 
subgroup analysis.20 However, the conclusions drawn by the authors and Medicines Health 
Regulatory Authority (MHRA) with respect to convalescent plasma risks conflating absence of 
evidence of a small effect with evidence that there is no benefit. However, re-analysis of the original 
data using Bayesian methods yields a small 
probability (>15%) of an effect of with an NNT of 100 across the whole trial, with an even higher 
probabilities of 90% and 75% 
respectively in patients who present within 7 days of symptoms, or who 
are antibody negative in presentation.  
The population who present early are easy to identify (from history alone) and 
constitute more than a third of the whole trial population. The estimated chance of a benefit with an 
NNT of 100 changes from ~7% in those who present late to ~90% in those who present early.   
Many clinicians, patients and their families might consider benefits in the region of one life saved 
for every 100 or 200 people treated as meaningful benefits. From a societal perspective, the 
treatment would need to achieve a mean of only one quality adjusted life year to justify a £20,000 
treatment cost. However, it is not our intention to prove that CP is a cost effective treatment – at 
heart that is a value judgement. We wish only to show that the conclusion that the treatment is in-
effective is unlikely to be true for people who have not developed immunity at the point where the 
therapeutic decision is 
 
 
made. It is always important to consider the literature in the round when making policy 
made. It is always important to consider the literature in the round when making policy 
made. It is 
always important to consider the literature in the round when making policy 
recommendations. Previous trials have been small and underpowered, with a recent 
meta-analysis of evaluations of CP in COVID identifying less than 2,000 patients across all RCT’s prior 




   
 
   
 
with 34/105 deaths23 in the seronegative placebo arm and 65/228 deaths in the CP arm, a RR of 
death with CP 1.12 but with very wide Confidence Intervals (95%CI: 0.51- 2.43). A further trial (which 
stopped early due to declining case numbers), recruited older adults within 72 hours of symptoms.16 
In this study, 13/80 patients (16%) who received CP developed severe disease, while 25/80 (31%) of 
the placebo arm, a relative risk of 0.52 (95% CI 0.29-0.94) in favour of CV. In a recent case series of 
14 immunocompromised patients with COVID-19 who had no detectable SARS-CoV-2 IgG, 
transfusion of CP was associated with clinical improvement and the degree of clinical improvement 
correlated with the IgG titre post transfusion. Finally, the largest observational study in hospitalised 
patients (n = 3,082), a US registry study (published after RECOVERY), identified a lower risk of death 
in patients transfused early with higher levels of SARS-CoV-2 IgG antibody. Taken in the round the 
literature supports our re-analysis of the RECOVERY data showing a benefit of CP among 
immunologically naïve patients with COVID
.24 Yet further support for our conclusion can be found from secondary outcomes in the  RECOVERY 
trial that we would expect to correlate with the primary outcome if the hypothesis that CP is 
particularly effective in immunologically naïve patients.  
Both secondary outcomes (discharge home by day 28, and invasive mechanical ventilation or death) 
Both secondary outcomes (discharge home by day 28, and invasive mechanical ventilation or death) 
Both secondary outcomes (discharge home by day 28, and 
invasive mechanical ventilation or death) in the original study showed heterogeneity with respect to 
serological status and intervention effect with impressive p values of 0.008 and 0.01 respectively in 
favour of CP. Although we do not focus on this to avoid accusations of ‘cherry picking’ the data, this 
is entirely consistent with and supportive of a causal path by with CP reduces mortality, and both of 
these are critical outcomes relevant to both patients and clinicians. 
We recognize that there may have been chance imbalances in age or comorbidity within the 
We recognize that there may have been chance imbalances in age or comorbidity within the 
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Conclusions: 
The RECOVERY trial for CP reported no benefit. Recognising the changing literature since the trial 
started and using a variety of priors, we suggest the reporting of no effect may be premature. It 
remains plausible that CP has a small, but clinically important effect on mortality in those who have 
not already developed an antibody response or who present early. It is clear that any effect is likely 
small, but we would argue clinicians, scientists, and government agencies to review all trial data in 
totality, rather than regarding the null result as fixed. 
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